# US 2019/0317097 A1 · Novel Biomarkers for Sub-Typing Pancreatic Ductal Adenocarcinoma

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0317097 A1
- Document ID: US20190317097A1
- Status: Published application
- Kind: A1
- Application number: 16/422,778
- Filed: 2019-05-24
- Published: 2019-10-17
- Earliest claimed: 2012-10-12
- Assignees: Hi-Stem Ggmbh
- Applicants: Hi-Stem Ggmbh
- Inventors: Christian Thomas Eisen; Andreas Trumpp; Martin Ronald Sprick
- Web page: https://patentgrep.com/patent/US20190317097A1

## CPC

- G01N 33/57525: of the liver or pancreas
- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- C12Q 1/6888: for detection or identification of organisms
- C12Q 2600/112: Disease subtyping, staging or classification
- C12Q 2600/158: Expression markers
- G01N 2333/47: Assays involving proteins of known structure or function as defined in the subgroups
- G01N 2333/4742: Keratin; Cytokeratin
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- G01N 2800/56: Staging of a disease; Further complications associated with the disease
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

This invention relates to novel approaches for the identification and stratification of subtypes of pancreatic ductal adenocarcinoma (PDAC), in particular to novel PDAC subtype-specific markers, and to diagnostic kits comprising reagents for detecting said markers.

## Claims

### Claim 1

In vitro method for the subtype-specific detection of PDAC cells in a tumor sample characterized by (A) the step of detecting expression of subtype-specific markers, either as proteins or as oligonucleotides encoding such proteins, wherein keratin 81 and vimentin are detected as markers for PDAC cells of the quasi-mesenchymal subtype, wherein (i) one or more transcription factors selected from HNF-1A, HNF-1B, FOXA2 (HNF3B), FOXA3 (HNF3G), HNF4G, and ONECUT1 (HNF6), (ii) one or more target genes regulated by HNF-1A, particularly the HNF-1A target genes listed in Table 2, and (iii) cadherin17 (CDH17) are detected as markers for cells of the exocrine-like subtype, and wherein PDAC cells of the classical subtype are characterized by the absence of (i) keratin 81 and/or vimentin, and (ii) HNF-1A and/or HNF-1B, or characterized by (B) the step of detecting expression of subtype-specific markers, either as proteins or as oligonucleotides encoding such proteins, wherein keratin 81 is the marker for PDAC cells of the quasi-mesenchymal subtype, wherein HNF-1A is the marker for cells of the exocrine-like subtype, and wherein PDAC cells of the classical subtype are characterized by the absence of keratin 81 and HNF-1A.

### Claim 2

(canceled)

### Claim 3 (depends on 1)

The in vitro method of claim 1, wherein PDAC of the classical subtype are identified by determining the absence of specific expression of one or more additional biomarkers selected from (i) transcription factors selected from HNF-1A, HNF-1B, FOXA2 (HNF3B), FOXA3 (HNF3G), HNF4G, and ONECUT1 (HNF6), (ii) one or more target genes regulated by HNF-1A, particularly the HNF-1A target genes listed in Table 2, and (iii) cadherin17 (CDH17).

### Claim 4 (depends on 1)

The in vitro method according to claim 1, wherein said detection is based on binding of a detection antibody to an epitope of one of said subtype-specific markers, particularly wherein said in vitro method comprises the steps of:
(a) bringing said sample into contact with a detection antibody specific for one of said subtype-specific markers under conditions that allow binding of the detection antibody to said epitope;
(b) removal of excess detection antibody molecules; and
(c) detection of bound detection antibody in said sample.

### Claim 5

(canceled)

### Claim 6 (depends on 4)

The in vitro method according to claim 4, wherein the detection antibody is a monoclonal antibody, a polyclonal antibody, a recombinantly produced antibody, including a recombinantly produced chimeric or humanized antibody, a fully synthetic antibody, or a functional fragment of one of said antibodies.

### Claim 7 (depends on 4)

The in vitro method according to claim 4, wherein detection antibody binding is detected by incubation with a secondary antibody, particularly a labeled secondary antibody.

### Claim 8 (depends on 4)

The in vitro method according to claim 4, wherein the secondary antibody is labeled with a marker molecule, particularly wherein the secondary antibody is labeled with a fluorescent dye, a biologically active enzymatic label, a radioactive label, a nuclear magnetic resonance active label, a luminescent label or a chromophoric label.

### Claim 9

(canceled)

### Claim 10 (depends on 8)

The in vitro method according to claim 8, wherein the radioactive label is selected from the group of 32P, 125I, 3H, 14C, 188Rh, 131I, 99mTc and 111In.

### Claim 11 (depends on 10)

The in vitro method according to claim 10, wherein antibody binding is detected by immunohistological staining.

### Claim 12 (depends on 1)

The in vitro method according to claim 1, wherein said detection is based on determining mRNA encoding one of said subtype-specific markers, particularly by quantitative real-time polymerase chain reaction (qRT-PCR).

### Claim 13

In vitro method for the subtype-specific detection of PDAC cells in a tumor sample, characterized by the step of analyzing the Src inhibitor sensitivity signature in a gene expression profile, particularly wherein the gene expression profile is based on the set of 30 genes as shown in Table 1

### Claim 14 (depends on 1)

The in vitro method according to claim 1, wherein said sample contains pancreatic tissue.

### Claim 15 (depends on 14)

The in vitro method according to claim 14, wherein said sample is obtained from a mammal, particularly a human.

### Claim 16

Kit for the subtype-specific detection of PDAC cells comprising at least two reagents specific for PDAC subtype-specific markers selected from the list of: (i) keratin 81, (ii) vimentin, (iii) one or more transcription factors selected from HNF-1A, HNF-1B, FOXA2 (HNF3B), FOXA3 (HNF3G), HNF4G, and ONECUT1 (HNF6), (iv) one or more target genes regulated by HNF-1A, particularly the HNF-1A target genes listed in Table 2, and (v) cadherin17 (CDH17), wherein said reagents are selected from the list of: detection antibodies and oligonucleotide probes, and optionally further comprising at least one reagent for the detection of at least one of said reagents.

### Claim 17 (depends on 16)

The kit of claim 16, comprising (i) at least one reagent specific for the quasi-mesenchymal selected from the list of: keratin 81 and vimentin, particularly keratin 81, and (ii) at least one reagent specific for the exocrine-like PDAC subtypes selected from the list of: HNF-1A and HNF-1B, particularly HNF-1A.

### Claim 18

A kit for the subtype-specific detection of Src inhibitor-sensitive PDAC cells comprising oligonucleotide probes for the identification of a Src inhibitor sensitivity signature, particularly comprising oligonucleotide probes representing the 30 genes shown in Table 1.

### Claim 19

A method of stratifying patients suffering from PDAC into treatment cohorts, the method comprising:
(A) the steps of:
(a) in vitro determination of (i) the expression and/or the presence of (i) keratin 81, (ii) vimentin, (iii) one or more transcription factors selected from HNF-1A, HNF-1B, FOXA2 (HNF3B), FOXA3 (HNF3G), HNF4G, and ONECUT1 (HNF6), (iv) one or more HNF-1A target genes, particularly the HNF-1A target genes listed in Table 2, and/or (v) cadherin17 (CDH17);
(b) identifying the PDAC subtype based on the expression and/or the presence of the selected proteins;
(c) stratifying PDAC patients into drug treatment cohorts based on the PDAC subtype they are suffering from; or
(B) the steps of:
(a) establishing an in vitro gene expression profile for the determination of the Src inhibitor sensitivity signature in cells of a patient sample containing pancreatic tissue;
(b) identifying the PDAC subtype based on the gene expression profile;
(c) stratifying PDAC patients into drug treatment cohorts based on the PDAC subtype they are suffering from.

### Claim 20

(canceled)

### Claim 21 (depends on 19)

The method according to claim 19, wherein said method represents a method of evaluating the prognosis of patients suffering from PDAC.

### Claim 22

(canceled)

### Claim 23 (depends on 19)

The method according to claim 19, wherein the expression level is determined on mRNA level by quantitative real-time polymerase chain reaction (qRT-PCR), or wherein the expression level is determined on protein level based on detection of antibody binding to the selected proteins.

### Claim 24

(canceled)

### Claim 25 (depends on 19)

The method according to claim 19, wherein said cells are obtained by purifying cancer cells from said patient sample, particularly wherein the purifying step comprises flow sorting or laser capture microdissection.

### Claim 26 (depends on 19)

The method according to claim 19, wherein said patient sample is a tumor biopsy, particularly wherein said tumor biopsy is obtained by fine needle aspiration.

### Claim 27

(canceled)
